Licensing status

Publication and contact information



c-Myc (MYC); plasmacytoma variant translocation 1 oncogene (PVT1)

Studies in patient samples and cell culture suggest inhibiting PVT1 could be useful for treating MYC-driven cancers. In murine cells with amplification of the chromosomal region containing Myc, Pvt1 siRNA decreased proliferation compared with control siRNA. In 8,657 human tumor samples with amplification of this chromosomal region, 98% showed increased copies of both MYC and PVT1. In mice, injection of PVT1-deficient, MYC-driven human colorectal cancer cells resulted in decreased tumor formation and tumor growth compared with injection of cells expressing PVT1. Next steps include elucidating how PVT1 modulates MYC expression and activity in cancer and developing chemical screens to identify small molecules that could disrupt PVT1-MYC cooperation.

SciBX 7(28); doi:10.1038/scibx.2014.823
Published online July 24, 2014

Patent and licensing status undisclosed

Tseng, Y.-Y. et al. Nature; published online June 22, 2014;
Contact: Anindya Bagchi, University of Minnesota, Minneapolis, Minn.